I would like to see Titan finance the rest of the development cost through credit instruments, and then do a raise/uplist at FDA approval to cover debt and fund the product launch. I think they could easily get a valuation of over $1B with a final product and FDA approval in hand, which would allow them to do an offering at $6-7/share instead of 60-70 cents.
Now that I think about it, perhaps the independent analysis from Next Level Analytics that was funded by Titan was designed to make the case to a creditor for just this kind of arrangement? (Note: I have no idea if this is true...just idle speculation)